Bullish & Foolish
Full MRKR fundamentals All 466 on the Survival Watch

MRKRMARKER THERAPEUTICS, INC.

Is Marker Therapeutics struggling financially?

Yes, by its own account. Marker Therapeutics told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

20/100

Fragile

Sector
Biotech/Pharma
Market cap
$23.2M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 6months

    If the burn speeds up

    Empty by Dec 2026

  • 9months

    If it eases off

    Empty by Mar 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$11.3M

÷

Cash burned over the last 12 months

$18.5M

What Marker Therapeutics told the SEC

…into the first quarter of 2027 assuming no additional grant funds are received, either from new grants or from existing awarded grants. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. Management is considering raising additional capital through the issuance of securities and intends to apply for additional grant funds, which could enable the Company to fund its…

MARKER THERAPEUTICS, INC., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 54.0% share-count increase The company issued stock. Each share now owns 35.1% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt